-
公开(公告)号：US20230398173A1
公开(公告)日：2023-12-14
申请号：US18456852
申请日：2023-08-28
发明人： Angelika Fretzen , Mark G. Currie , Ahmad Hashash , Mahendra Dedhiya , Yun Mo , Anil Chhettry , Matthew Miller , Ritesh Sanghvi , Mohammad Mafruhul Bari , Andreas Grill
CPC分类号： A61K38/10 , A61K9/1611 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2846 , A61K9/4891 , A61K9/1676 , A61K9/5026 , A61K9/5042 , A61K9/284 , A61K9/2886 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/4808 , A61K9/1652 , A61K9/4825
摘要： The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
-
公开(公告)号：US20230346881A1
公开(公告)日：2023-11-02
申请号：US18348688
申请日：2023-07-07
发明人： Yun Mo , Angelika Fretzen , Brian Cali , Mahendra Dedhiya
CPC分类号： A61K38/12 , A61K9/1611 , A61K9/1641 , A61K9/1676 , A61K38/10 , A61K47/18
摘要： The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
-
3.发明申请公开(公告)号：US20220125734A1
公开(公告)日：2022-04-28
申请号：US17570713
申请日：2022-01-07
发明人： Angelika Fretzen , Steven Witowski , Alfredo Grossi , Hong Zhao , Mahendra Dedhiya , Yun Mo
IPC分类号： A61K9/50 , A61K9/16 , A61K9/20 , A61K9/48 , A61K38/10 , A61J3/00 , A61K38/12 , A61K47/02 , A61K47/18 , A61K47/36 , B65D81/26 , G01N30/02
摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
-
4.发明授权Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol 有权奈比洛尔及其药学上可接受的盐，制备方法和奈比洛尔的药物组合物公开(公告)号：US08633241B2
公开(公告)日：2014-01-21
申请号：US13859226
申请日：2013-04-09
IPC分类号： A61K31/35
CPC分类号： C07D407/12 , A61K9/2018 , A61K9/2054 , A61K9/2059 , C07D311/58 , C07D407/04
摘要： The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts.The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
摘要翻译： 本发明提供了奈比洛尔或其药学上可接受的盐，特别是式（I）的盐酸盐的合成的改进方法。 本发明还提供奈比洛尔及其药学上可接受的盐的新型T1。 本发明还提供了用于制备式（I）盐酸奈必洛尔的固体口服剂型的药物组合物和方法，而不使用润湿剂，并且任选地使用粘合剂和/或崩解剂。
-
公开(公告)号：US20140005128A1
公开(公告)日：2014-01-02
申请号：US13816154
申请日：2011-08-11
申请人： Yun Mo , Angelika Fretzen , Brian Cali , Mahendra Dedhiya
发明人： Yun Mo , Angelika Fretzen , Brian Cali , Mahendra Dedhiya
IPC分类号： A61K38/10
CPC分类号： A61K38/12 , A61K9/1611 , A61K9/1641 , A61K9/1676 , A61K38/10 , A61K47/18
摘要： The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
摘要翻译： 本发明涉及包含利那洛肽或其药学上可接受的盐的稳定的药物组合物，以及用于制备和使用组合物的各种方法和方法。
-
公开(公告)号：US20130059797A1
公开(公告)日：2013-03-07
申请号：US13505926
申请日：2010-11-03
申请人： Jeffrey Johnston , Angelika Fretzen , Steven Witowski , Alfredo Grossi , Hong Zhao , Bernard Joseph Lavins , Mahendra Dedhiya , Harvey Schneier
发明人： Jeffrey Johnston , Angelika Fretzen , Steven Witowski , Alfredo Grossi , Hong Zhao , Bernard Joseph Lavins , Mahendra Dedhiya , Harvey Schneier
摘要： The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
摘要翻译： 本发明提供了通过施用治疗有效剂量的利那洛肽来治疗患有慢性便秘的患者的方法。
-
7.发明申请Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration 审中-公开适用于口服给药的GC-C受体激动剂多肽的稳定制剂公开(公告)号：US20120213846A1
公开(公告)日：2012-08-23
申请号：US13059154
申请日：2009-08-14
申请人： Angelika Fretzen , Steven Witowski , Alfredo Grossi , Hong Zhao , Mahendra Dedhiya , Yun Mo
发明人： Angelika Fretzen , Steven Witowski , Alfredo Grossi , Hong Zhao , Mahendra Dedhiya , Yun Mo
CPC分类号： A61K9/50 , A61J3/00 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/167 , A61K9/205 , A61K9/2054 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5078 , A61K38/10 , A61K38/12 , A61K47/02 , A61K47/183 , A61K47/36 , B65D81/26 , G01N30/02 , G01N2030/027
摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
摘要翻译： 适用于口服给药的利那洛肽的固体稳定制剂在本文中描述为制备这些制剂的方法。 本文描述的制剂含有由氨基酸序列Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr（“linaclotide”）或其药学上可接受的盐组成的多肽。 本文所述的利那洛肽制剂是稳定的并且具有用于制造，储存和分配药物的足够的保质期。
-
公开(公告)号：US07838552B2
公开(公告)日：2010-11-23
申请号：US11273992
申请日：2005-11-15
IPC分类号： A61K31/352 , C07D311/04
CPC分类号： A61K31/40 , A61K31/54 , A61K45/06 , A61K2300/00
摘要： Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
-
9.发明授权公开(公告)号：US07829569B2
公开(公告)日：2010-11-09
申请号：US12117972
申请日：2008-05-09
申请人： Xiangmin Liao , Haijian Zhu , Andreas Grill
发明人： Xiangmin Liao , Haijian Zhu , Andreas Grill
IPC分类号： A61K31/4965 , C07D295/00
CPC分类号： C07D295/135
摘要： The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described.
摘要翻译： 本发明涉及新的溶剂化物和结晶形式的氨基甲酰基 - 环己烷衍生物，更具体地说，涉及新的溶剂化物和结晶形式的反式-1- {4- [2- [4-（2,3-二氯苯基） - 哌嗪-1 - 基] - 乙基] - 环己基} -3,3-二甲基 - 脲盐酸盐。 还描述了制备这些形式的方法，含有这些形式的组合物及其使用方法。
-
10.发明申请Memantine For The Treatment Of Mild And Mild To Moderate Alzheimer's Disease 审中-公开美容院用于治疗轻度和轻度的中度阿尔茨海默病公开(公告)号：US20100048726A1
公开(公告)日：2010-02-25
申请号：US12608046
申请日：2009-10-29
申请人： Scott McDonald , Ivan Gergel , Steven Potkin , Albrecht Stöffler , Yvonne Wirth , Hans-Joerg Moebius
发明人： Scott McDonald , Ivan Gergel , Steven Potkin , Albrecht Stöffler , Yvonne Wirth , Hans-Joerg Moebius
CPC分类号： A61K31/13
摘要： The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjects with mild, or mild-to-moderate Alzheimer's disease.
摘要翻译： 本发明提供了通过施用有效剂量的美金刚来治疗，预防或延缓轻度或轻度至中度阿尔茨海默氏病的进展的方法。 本发明还提供了一种用于在轻度或轻度至中度阿尔茨海默病的受试者中预防脑中皮质和亚皮质区域中葡萄糖代谢降低的方法。
-
-
-
-
-
-
-
-
-
搜索结果
76 条记录 (耗时 0.036 秒)
